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Background: Virus-like particles (VLPs) can be efficiently produced by heterologous expression of viral structural
proteins in yeast. Due to their repetitive structure, VLPs are extensively used for protein engineering and generation
of chimeric VLPs with inserted foreign epitopes. Hamster polyomavirus VP1 represents a promising epitope carrier.
However, insertion of large sized protein sequences may interfere with its self-assembly competence. The co-expression
of polyomavirus capsid protein VP1 with minor capsid protein VP2 or its fusion protein may result in pseudotype VLPs
where an intact VP1 protein mediates VLP formation. In the current study, the capacity of VP1 protein to self-assemble to
VLPs and interact with the modified VP2 protein has been exploited to generate pseudotype VLPs displaying large-sized
antibody molecules.
Results: Polyomavirus-derived pseudotype VLPs harbouring a surface-exposed functionally active neutralizing antibody
specific to hepatitis B virus (HBV) surface antigen (HBsAg) have been generated. The pseudotype VLPs consisting of an
intact hamster polyomavirus (HaPyV) major capsid protein VP1 and minor capsid protein VP2 fused with the anti-HBsAg
molecule were efficiently produced in yeast Saccharomyces cerevisiae and purified by density-gradient centrifugation.
Formation of VLPs was confirmed by electron microscopy. Two types of pseudotype VLPs were generated harbouring
either the single-chain fragment variable (scFv) or Fc-engineered scFv on the VLP surface. The antigen-binding activity
of the purified pseudotype VLPs was evaluated by ELISA and virus-neutralization assay on HBV-susceptible primary
hepatocytes from Tupaia belangeri. Both types of the pseudotype VLPs were functionally active and showed a potent
HBV-neutralizing activity comparable to that of the parental monoclonal antibody. The VP2-fused scFv molecules were
incorporated into the VLPs with higher efficiency as compared to the VP2-fused Fc-scFv. However, the pseudotype
VLPs with displayed VP2-fused Fc-scFv molecule showed higher antigen-binding activity and HBV-neutralizing capacity
that might be explained by a better accessibility of the Fc-engineered scFv of the VLP surface.
Conclusions: Polyomavirus-derived pseudotype VLPs harbouring multiple functionally active antibody molecules with
virus-neutralizing capability may represent a novel platform for developing therapeutic tools with a potential
application for post-exposure or therapeutic treatment of viral infections.* Correspondence: azvirb@ibt.lt
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Table 1 The list of recombinant plasmids for the expression of
pseudotype VLPs in yeast S. cerevisiae
Plasmid Protein Short name
pFGG3-VP1/VP2-Fc-scFv VP1/scFv-Fc-VP2 Construct #1
pFGG3-VP1/VP2-scFv VP1/scFv-VP2 Construct #2
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Viral structural proteins produced by heterologous ex-
pression may have the intrinsic ability to spontaneously
self-assemble into highly organized particles – virus-like
particles (VLPs) – that morphologically resemble viral
capsid and represent a promising tool for protein engin-
eering. The simplest VLPs are composed of a single viral
structural protein, such as the assembly-competent en-
velope or capsid protein [1–4]. More complex recombin-
ant VLPs can be generated by either genetic fusion or
co-expression of the VLPs with an additional target pro-
tein or its segment. The co-expression of the assembly-
competent viral structural protein with another viral
structural protein or its fusion protein results in so-
called pseudotype VLPs [3, 5]. Previous studies show
that the major capsid protein VP1 of different polyoma-
viruses can be efficiently produced in yeast expression
system in a form of VLPs [6] consisting of 72 pentamers
of the VP1 protein [7]. Hamster polyomavirus (HaPyV)
VP1 protein has been exploited for the generation of
either chimeric VLPs harbouring foreign epitopes, or
pseudotype VLPs when co-expressed with the minor
capsid protein VP2 that binds within the central 5-fold
cavity of each VP1 pentamer [8–11]. Moreover, it was
demonstrated that HaPyV-derived pseudotype VLPs rep-
resent an efficient carrier for functionally active complex
molecules, such as antibodies [12]. In these pseudo-
type VLPs, an intact VP1 protein is functioning as a
carrier mediating VLP formation of both VP1 and the
modified VP2 protein molecule. The C-terminal part
of VP2 protein is necessary for its interaction with
VP1 pentamer, therefore, the VP2 N-terminus can be
shortened and used to join target molecules. The ra-
tio of VP1:VP2 proteins in HaPyV capsid is 360:72
[7], consequently up to 72 chimeric VP2 molecules
harbouring target molecules might be incorporated
into one VLP. Based on the structure of polyomavirus
capsids [13, 14], it was predicted that the inserted tar-
get sequence can be displayed on the surface of pseu-
dotype VLPs. In contrast to chimeric VLPs that do
not tolerate long inserts, this approach allowed effi-
cient presentation of large-sized foreign protein se-
quences as demonstrated for the full-length human
tumor-associated antigen Her2 [15, 16], prostate-
specific antigen [17], green fluorescent protein [18],
cellular marker p16INK4A [19] and the antibody mol-
ecule [12]. The first example of a successful expres-
sion of a large recombinant antibody molecule on the
surface of VLPs was generation of HaPyV-derived
pseudotype VLPs harbouring the Fc-engineered single-
chain antibody (scFv-Fc) specific to bacterial cytolysin
vaginolysin (VLY). In this study, the scFv derived
from hybridoma cell line producing high-affinity neu-
tralizing antibody against VLY [20] was fused withhuman IgG1 Fc domain comprising the CH2 and
CH3 domains and the hinge region [21]. To join the
scFv-Fc molecule, the N-terminus of VP2 protein was
deleted and replaced by the scFv-Fc molecule. It was
demonstrated that the VLY-specific scFv-Fc fused with
HaPyV VP2 protein and co-expressed with VP1 pro-
tein in the form of pseudotype VLPs was properly
folded and exhibited a strong VLY-binding activity
comparable to that of the parental monoclonal anti-
body (MAb). In contrast, the attempts to produce
non-tagged, hexahistidine-tagged and alpha factor-
tagged scFv-Fc proteins in yeast were unsuccessful
due to their low yield, instability and a tendency to
form insoluble aggregates [12, 22–24]. Therefore, an
approach to display multiple functionally active anti-
body molecules on the surface of pseudotype VLPs
that can be easily purified by density-gradient centri-
fugation may provide a promising alternative to other
currently available methods for producing recombin-
ant antibodies.
In the current study, we describe generation of
polyomavirus-derived pseudotype VLPs harbouring
surface-exposed scFv and scFv-Fc molecules specific
to hepatitis B virus surface antigen (HBsAg). To our
knowledge, this is the first example of pseudotype
VLPs with an anti-viral activity.
Results
Generation in yeast of recombinant proteins harbouring
anti-HBsAg molecule
To generate pseudotype VLPs with surface-exposed
HBsAg-specific antibody molecule, the gene encoding
anti-HBsAg was fused with gene encoding modified
HaPyV minor capsid protein VP2 and co-expressed
together with the gene encoding HaPyV major capsid
protein VP1. To join the anti-HBsAg molecule, the
N-terminus of the VP2 protein was truncated by 100
amino acid (aa) residues. The production of both
HaPyV VP1 protein and the modified VP2 protein
was induced by adding galactose into yeast growth
medium. Anti-HbsAg scFv comprising variable regions
of mouse IgG in the orientation of VL-(G4S)4-VH was
derived from the in-house produced hybridoma HB1
secreting neutralizing MAb against HBsAg (unpub-
lished data). The cDNA sequences encoding VH and
VL regions of anti-HBsAg MAb were deposited in
GenBank under accession numbers KP972453 and
Fig. 2 Analysis of recombinant proteins (constructs #1 and #2)
partially purified on sucrose gradient by SDS-PAGE. The asterisk
indicates the position of VP1 protein; the arrow indicates the position
of VP2-fused protein. Prestained protein weight marker (Thermo Fisher
Scientific) is presented on the right of each panel
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specific antibody molecule were produced in yeast S.
cerevisiae strain AH22-214p: one carrying the scFv-Fc
molecule and one carrying the scFv without the Fc
part (Table 1, Fig. 1).
After induction of the synthesis of recombinant pro-
teins, the lysates of harvested yeast cells were exam-
ined by SDS-PAGE to evaluate the expression of VP1
and the scFv-Fc-VP2 fused proteins and then subjected
to ultracentrifugation on sucrose density gradient. The
analysis of partially purified recombinant proteins
VP1/scFv-Fc-VP2 and VP1/scFv-VP2 (constructs #1,
#2) by SDS-PAGE revealed a protein band of ap-
proximately 42 kDa that was identified as an intact
VP1 protein (Fig. 2, the position indicated by an as-
terisk). Protein band of 78.4 kDa corresponding to
the molecular mass of scFv-Fc-VP2 fusion protein
was detected in the construct #1 (Fig. 2, the position
indicated by an arrow). Protein band of 52.5 kDa corre-
sponding to the molecular mass of scFv-VP2 fusion pro-
tein was detected in the construct #2 (Fig. 2, the position
indicated by an arrow). As demonstrated by SDS-PAGE,
the yield of recombinant proteins after the first purifica-
tion step was similar and varied from 0.3 to 0.5 mg from
1 g of wet yeast biomass. The constructs #1 and #2 did
not differ significantly in the expression levels of an intact
VP1 protein.
Purification and electron microscopy analysis of
recombinant proteins harbouring anti-HBsAg molecule
HaPyV-derived recombinant proteins VP1/scFv-Fc-VP2
(construct #1) and VP1/scFv-VP2 (construct #2) were
successfully purified by the method adapted for the
purification of VLPs using CsCl density centrifugation.
The analysis of purified recombinant proteins by
SDS-PAGE revealed the expected homogenous protein
bands of 78.4 kDa and 42 kDa in case of construct
#1 (Fig. 3a, lane 1) and homogenous protein bands of
52.5 kDa and 42 kDa in case of construct #2 (Fig. 3a,
lane 2). Western blot with the HaPyV VP1-specific
MAb 3D10 immunostained the 42 kDa protein band
in both constructs #1 and #2 thus confirming the
identity of the VP1 protein (Fig. 3b, lanes 1, 2). As a
positive control for Western blot with VP1-specific MAb
3D10, the construct consisting of an intact HaPyV VP1
protein and the VP2 fuse with green fluorescent protein
(eGFP) was used (VP1/GFP-VP2, Fig. 3b, lane 3). WesternFig. 1 Schematic representation of recombinant proteins harbouring anti-Hblot with HRP-labelled anti-human IgG antibody immu-
nostained the 78.4 kDa band present in construct #1
thus confirming the identity of scFv-Fc-VP2 fusion
protein (Fig. 3c, lane 1). No specific staining was ob-
tained with construct #2 lacking the Fc part of hu-
man IgG (Fig. 3C, lane 2). As a positive control for
Western blot with anti-human IgG, purified human
IgG was used (Fig. 3C, lane 4).
As calculated from the SDS-PAGE with subsequent
densitometry analysis, the VP1: scFv-Fc-VP2 ratio (w/w)
in the VP1/scFv-Fc-VP2 (construct #1) is approximately
13:1, while the ratio the VP1: scFv-VP2 (w/w) in the
VP1/scFv-VP2 (construct #2) is approximately 6:1. Based
on the molecular weight (MW) of the VP2-fused pro-
teins (78.4 kDa and 52.5 kDa, respectively), the calcu-
lated average number of the scFv-Fc-VP2 fused protein
per one pseudotype VLP was 14 (construct #1), while
the calculated number of the scFv-VP2 fused protein per
one pseudotype VLP was 46 (construct #2).BsAg molecule
Fig. 3 Analysis of recombinant constructs VP1/scFv-Fc-VP2 (construct #1, lane 1) and VP1/scFv-VP2 (construct #2, lane 2) purified on CsCl gradient by
SDS-PAGE (a) and Western blot with the MAb 3D10 (b) and anti-human IgG antibody (c). Protein band corresponding to MW of 78.4 kDa represents
scFv-VP2 fused protein (lane 1), protein band of 52.5 kDa represents scFv-VP2 fused protein (lane 2) and protein band of 42 kDa represents VP1 protein
(lanes 1–3). The construct VP1/GFP-VP2 (lane 3) and purified human IgG (lane 4) are used as positive controls for Western blot
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stained and subjected to electron microscopy (EM) ana-
lysis that confirmed an efficient self-assembly of both re-
combinant proteins to VLPs (Fig. 4). The pseudotype
VLPs were approx. 45–50 nm in diameter, which corre-
sponds to the size of intact HaPyV capsids and the un-
modified recombinant HaPyV VP1-derived VLPs [8].
The size and shape of VP1/scFv-Fc- VP2 pseudotype
VLPs (A) and VP1/scFv-VP2 pseudotype VLPs (B) were
similar to that of VP1/GFP-VP2 pseudotype VLPs used
as a positive control (C). The purified pseudotype VLPs
were further analysed for the HBsAg-binding activity
and the ability to neutralize HBV.
HBV-neutralizing activity of pseudotype VLPs harbouring
anti-HBsAg molecule
Antigen-binding activity of the purified pseudotype VLPs
was confirmed by an indirect ELISA using recombinant
yeast-derived HBsAg (ayw) coated on the microtiter
plate and the HaPyV VP1-specific MAb 3D10 as a de-
tection antibody. Both anti-HBsAg fused proteins dis-
played on the respective pseudotype VLPs were reactive
with the immobilized HBsAg (Fig. 5). The scFv-Fc-VP2
fused protein (construct #1) showed antigen-binding ac-
tivity in a similar concentration range (starting fromFig. 4 Electron microscopy pictures of CsCl-purified pseudotype VLPs stained
268 electron microscope. a, VP1/scFv-Fc-VP2 pseudotype VLPs (construct #1);
pseudotype VLPs (control). Scale bar – 100 nm1.5 × 10−12 M) as the parental MAb HB1 used as a posi-
tive control (starting from 0.7 × 10−12 M). Meanwhile,
the scFv-VP2 fused protein (construct #2) was reactive
with the plate-bound HBsAg when added at concentra-
tions exceeding 24 × 10−12 M. The VP1/GFP-VP2 pseudo-
type VLPs used as a negative control did not show any
reactivity with the immobilized antigen, which confirms
the specificity of the ELISA (Fig. 5). Furthermore, the abil-
ity of the purified pseudotype VLPs to neutralize HBV was
assayed in vitro using the HBV infection model of primary
Tupaia hepatocytes (PTH) [25]. The neutralizing potency
of the pseudotype VLPs was evaluated in comparison to
the parental monoclonal antibody HB1 used as a positive
control. The pseudotype VLPs were used at amounts that
correspond to 0.5 μg/mL to 8 μg/mL of the anti-HBsAg
fused proteins. The VP1/scFv-Fc-VP2 pseudotype VLPs
containing the Fc part of human IgG1 (construct #1)
showed higher HBV-neutralizing potency as compared to
VP1/scFv-VP2 pseudotype VLPs (construct #2): 1 μg/mL
(1.27 × 10−10 M) of scFv-Fc-VP2 fused protein displayed
on the pseudotype VLPs (construct #1) were sufficient to
induce complete HBV neutralization while 1 μg/mL
(1.9 × 10−10 M) of the scFv-VP2 fused protein dis-
played on the pseudotype VLPs (construct #2) in-
duced only partial HBV neutralization (Fig. 6). Thewith 2 % aqueous uranyl acetate solution and analysed by Morgagni
b, VP1/scFv-VP2 pseudotype VLPs (construct #2), c, VP1/GFP-VP2
Fig. 5 HBsAg-binding activity of pseudotype VLPs harbouring anti-HBsAg molecules determined by ELISA. Concentrations (pM) of anti-HBsAg
fused proteins scFv-Fc-VP2 and scFv-VP2 displayed on the respective pseudotype VLPs are indicated. As a positive control, full-length parental
MAb HB1 is used. As a negative control, VP1/GFP-VP2 pseudotype VLPs are used
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VLPs VP1/scFv-Fc-VP2 (construct #1) containing
1 μg/mL (1.27 × 10−10 M) of scFv-Fc-VP2 fused pro-
tein was comparable to that obtained with 1 μg /mL
(0.67 × 10−10 M) of the full-length parental MAb HB1.
The specificity of the neutralization test was con-
firmed by the use of HaPyV-derived VP1/GFP-VP2
pseudotype VLPs (negative control) that did not induce
HBV neutralization. The incomplete HBV neutralizationFig. 6 HBV-neutralizing activity of pseudotype VLPs harbouring anti-HBsAg
Concentrations (μg/mL) of anti-HBsAg fused proteins scFv-Fc-VP2 and scFv
construct #2) are indicated. Highly purified HBV was preincubated with the
afterwards added to PTHs for 16 h at 37 °C. As a negative control, VP1/GFP
infected PTH cultures was determined on day 11. The red line indicates theby the construct #2 harbouring the scFv without the
Fc part might indicate that the scFv molecule is less
accessible on the surface of pseudotype VLPs as com-
pared to the Fc-engineered scFv. The results of the
HBV-neutralization test are consistent with the results
of an indirect ELISA (Fig. 5) where the scFv-Fc-VP2
fused protein displayed on the VLPs showed higher
antigen-binding activity as compared to the scFv-VP2
fused protein.molecule in comparison to the full length parental antibody (MAb).
-VP2 displayed on the respective pseudotype VLPs (construct #1 and
indicated quantities of the respective proteins for 1 h at 16 °C and
-VP2 at concentration 8 μg/mL is used. Newly produced HBsAg of
Cut-off
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Recombinant VLPs are extensively used for various appli-
cations, from basic virus assembly and structure studies to
the production of human and animal vaccines [3–5]. Due
to their repetitive structure, VLPs represent an efficient
carrier for B and T cell epitopes [4, 8, 10, 11]. Presentation
of large protein sequences on VLPs may broaden the
spectrum of potential VLP applications, however the
long-sized inserts may interfere with the self-assembly
competence of the viral carrier protein. To overcome this
problem, pseudotype VLPs composed of different viral
proteins can be generated. In the current study, the cap-
acity of HaPyV-derived major capsid protein VP1 to self-
assemble to VLPs and interact with the modified minor
capsid protein VP2 has been exploited to generate pseu-
dotype VLPs with surface-exposed multiple anti-HBsAg
molecules. The pseudotype VLPs expressed in yeast and
purified by density-gradient centrifugation were function-
ally active and showed a potent HBsAg-binding and HBV-
neutralizing activity comparable to that of the parental
MAb. The produced pseudotype VLPs harbouring
surface-exposed anti-HBsAg molecules is the first ex-
ample of anti-viral VLPs with virus-neutralizing capability.
This approach may be further exploited to develop novel
anti-viral tools for a post-exposure treatment of viral in-
fections. Prevention of clinical disease in individuals
already exposed to viral infection is an important issue of
modern biomedicine. Recent advances in passive immu-
noprophylaxis of viral infections, such as rabies and hu-
man respiratory syncytial virus infection, are based on
monoclonal antibody therapies [26, 27]. The in vivo stud-
ies have demonstrated the efficiency of neutralizing anti-
bodies in established infections of influenza A, HIV,
polioviruses, filoviruses and other viral infections [28–30].
The VLP approach combining the advantages of virus tar-
geting by the surface-exposed antibody molecule and the
capability of VLPs to encapsidate and deliver cargo, such
as therapeutic nucleic acids or proteins [31, 32] may pro-
vide new possibilities for the potential development of
effective anti-viral prophylactic and therapeutic strategies.
The current study demonstrates that antigen-binding
capability of the pseudotype VLPs depends on the struc-
ture of the antibody molecule displayed on the VLPs.
The anti-HBsAg molecule was presented on the VP2
protein in two different formats – either scFv alone or
Fc-engineered scFv comprising CH2 and CH3 domains
and the hinge region of human IgG1 [21]. The calcula-
tions based on the SDS-PAGE and densitometry data in-
dicate that the VP2 protein fused with 473 aa-long scFv
was incorporated into the pseudotype VLPs with higher
efficiency (approx. 46 molecules per VLP in construct
#2) as compared to 723 aa–long Fc-scFv (approx. 14
molecules per VLP in construct #1). However, construct
#2 containing 3 times higher amount of anti-HBsAgscFv molecules showed much lower HBsAg-binding ac-
tivity in ELISA and HBV-neutralizing potency in the
in vitro HBV infection assay as compared to construct
#1 harbouring Fc-engineered scFv molecules. The ob-
served difference might be explained by a better
accessibility of the Fc-engineered scFvs on the surface
of VLPs. The quantity of anti-HBsAg molecules incor-
porated into the pseudotype VLPs of our study (14
anti-HBsAg Fc-scFv-VP2 molecules per one VLP) is
consistent with a previous report where approx. 19
molecules of anti-VLY Fc-scFv-VP2 molecules were
found to be displayed the pseudotype VLP [20]. Based
on the resolved crystal structures of the virions of
SV-40 and murine polyomavirus, a maximum of 72
VP2 molecules could be incorporated into one pseudotype
VLPs as this corresponds to the number of VP1 protein
pentamers that compose the VLP [7, 13, 14]. The current
study clearly demonstrates that the number of large fusion
proteins to be incorporated into a pseudotype VLP may
vary according to the actual size of the modified VP2 mol-
ecule. Furthermore, the pseudotype VLPs harbouring mul-
tiple virus-neutralizing antibody molecules may represent
a promising platform for therapeutic vaccines against
acute or chronic viral infections. In case of HBV, construc-
tion of pseudotype VLPs combining different neutralizing
antibodies directed against both HBsAg and preS1 se-
quences [33, 34] might provide a potent anti-viral tool
with a broad HBV-neutralizing capacity. For human use,
the scFvs derived from human MAbs would be of special
interest [34] to avoid their enhanced immunogenicity after
presentation on pseudotype VLPs.
Conclusions
The current study demonstrates that HaPyV-derived
pseudotype VLPs are suitable carriers for antibody mole-
cules, both in the format of scFv and Fc-scFv. The pseu-
dotype VLPs harbouring the Fc-scFv-VP2 molecule show
higher antigen-binding activity and virus-neutralizing
potency as compared to those harbouring the scFv-VP2
molecule. This difference might be explained by a more
efficient exposure of the Fc-engineered scFv molecule on
the surface of the pseudotype VLPs as compared to the
scFv molecule.
The produced pseudotype VLPs harbouring surface-
exposed anti-HBsAg molecules is the first example of
anti-viral VLPs with virus-neutralizing capability.
The pseudotype VLPs harbouring multiple functionally
active antibody molecules with virus-neutralizing cap-
ability represents a novel platform for the construction
of therapeutic vaccines with a potential application for
post-exposure or therapeutic treatment of viral infections.
The VLP approach combining the advantages of virus tar-
geting by the surface-exposed antibody molecule and the
capability of VLPs to encapsidate and deliver cargo, such
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exploited for the development of novel efficient anti-viral
strategies.
Methods
Construction of HBsAg-specific single-chain fragment
variable (scFv)
All DNA manipulations were carried out according to
standard procedures [35]. Enzymes and kits for DNA
manipulations were purchased from Thermo Fisher
Scientific (Vilnius, Lithuania). The anti-HBsAg scFv
comprising variable regions of mouse IgG heavy (VH)
[GenBank: KP972453] and light chains (VL) [GenBank:
KP972454] in the orientation of VL-linker-VH was
cloned and constructed as described previously [12].
Briefly, total mRNA was isolated from 3 × 106 hybridoma
cells (clone HB1) using GeneJET RNA Purification Kit
(Thermo Fisher Scientific) according to manufacturer’s
recommendations. Hybridoma clone HB1 was produced
in-house using spleen cells of BALB/c mouse immunized
with recombinant HBsAg (unpublished data). The first
strand of cDNA was prepared using RevertAid™ H
Minus First Strand cDNA Synthesis Kit (Thermo
Fisher Scientific) according to manufacturer’s instruc-
tions. The cDNA corresponding to the variable re-
gions of mouse IgG VH and VL was obtained by
polymerase chain reaction (PCR) using sets of specific
primers described previously [12, 36]. In the second
PCR round, the VL and VH DNA fragments were
fused to yield the construction VL-(G4S)4-VH.
Construction of yeast expression plasmids
The anti-HBsAg scFv was displayed on the pseudotype
VLPs either alone or fused with the Fc region of human
immunoglobulin G1 encoded in pFUSE-hIgG1-Fc2 vec-
tor [21]. The resulting construction obtained by fusion
of anti-HBsAg scFv to human Fc region was named
scFv-Fc. Two yeast expression plasmids carrying either
the scFv or scFv-Fc DNA fragment were generated
(Table 1, constructs #1, #2). The recombinants were
screened in E. coli DH10B cells.
The plasmid pFGG3-VP1/ VP2-Fc-scFv used for the
co-expression of chimeric HaPyV-derived protein
scFv-Fc-VP2 and the intact HaPyV VP1 protein (con-
struct #1) were generated as described previously [12].
The construct encodes scFv-Fc molecule that is joined
at the N–terminus of the VP2 protein truncated by
100 amino acid (aa) residues. The plasmid pFGG3-
VP1/VP2-scFv encoding a similar construct without
the Fc part (construct #2) was generated by cloning
the scFv fragment into pFGG3-VP1/VP2Bg vector as
described previously [12]. The plasmid pFGG3-VP1/
VP2-eGFP was generated by cloning DNA fragment
encoding green-fluorescent protein into the bluntedXbaI and BglII sites of pFGG3-VP1/VP2Bg vector for
fusion to modified HaPyV VP2-encoding gene.Yeast strains, growth media and cultivation conditions
The constructed plasmids pFGG3-VP1/VP2-Fc-scFv
and pFGG3-VP1/VP2-scFv (Table 1), and pFGG3-VP1/
VP2-eGFP were used for the transformation of S. cerevi-
siae strain AH22-214p (a, leu2-3,112, his4-519, Δpep4).
Transformed yeast cells were cultivated as described pre-
viously [12]. Yeast biomass containing recombinant pro-
teins was harvested by centrifugation and stored at −20 °C
until purification. Yeast S. cerevisiae transformed with
pFGG3 vector without any insert was used as a negative
control.SDS-PAGE
Recombinant proteins were fractionated by electrophor-
esis on 12.5 % sodium dodecylsulfate-polyacrylamide
gels (SDS-PAGE) and then either visualized by staining
with Coomassie brilliant blue (Sigma–Aldrich, St. Louis,
MO, USA). The quantities of loaded recombinant
proteins were determined by densitometry using the
ImageScanner III (GE Healthcare, Little Chalfont, UK)
device supplied with the ImageQuantTL software. The
determination of the quantities of VP1 and VP2-fused
antibodies in the preparations of pseudotype VLPs was
based on the comparison with the known quantities of
VP1 and BSA proteins run in the same SDS-PAGE gel
and scanned by the ImageScanner III. The molar quan-
tities of VP1 and VP2-fused proteins in the samples of
purified VP1/scFv-Fc-VP2 and VP1/scFv-VP2 constructs
were calculated in accordance with their molecular
weight (MW). The average number of VP2-fused pro-
teins presented on one VLP was calculated as described
previously [12]. Briefly, concentrations of purified pseu-
dotype VLPs (mg/mL) were determined by Bradford
assay [37] and the known quantities of each construct
(1–3 μg per lane) were loaded on the SDS-PAGE gel. At
least three scans of each VLP preparation were obtained.
The determined quantities of VP1 protein (μg per lane)
and VP2-fused proteins (μg per lane) were calculated in
pmoles and then the number of protein molecules in
both analyzed VLP preparations were determined based
on the Avogadro constant. Assuming that 360 molecules
of VP1 protein are needed for the assembly of one VLP
[7] the calculated number of VP1 molecules was divided
by 360 to determine the number of VLPs in the re-
spective VLP preparation (VP1/scFv-VP2 VLPs and
VP1/scFv-Fc-VP2 VLPs). The average number of VP2-
fused molecules presented on one VLP was calculated
by dividing the number of the respective VP2-fused
molecules (scFv-VP2 and scFv-Fc-VP2) by the number
of VLPs in the sample.
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Recombinant proteins fractionated by SDS-PAGE were
electrotransferred to Immobilon P membrane (Millipore,
Bedford, MA, USA). The membranes were blocked with
5 % milk powder in phosphate-buffered saline (PBS) for
2 h at room temperature (RT) and rinsed in PBS with
1 % Tween-20 (PBST). For the detection of HaPyV VP1
protein, the membranes were incubated for 1 h at RT
with monoclonal antibody (MAb) 3D10 [10]. The MAb
was used at working dilution 1:1000 in PBST. The mem-
branes were then incubated with horseradish peroxidase
(HRP)-conjugated goat anti-mouse IgG (Bio-Rad) di-
luted 1:1000 in PBST. For the detection of scFv-Fc-VP2
fused protein, the membranes after blocking were incu-
bated with HRP-conjugated rabbit anti-human IgG (Bio-
Rad) diluted 1:2000 in PBST. After rinsing in PBST, the
enzymatic reaction was developed using tetramethylben-
zidine (TMB) chromogenic substrate (Sigma–Aldrich).
Purification of pseudotype VLPs harbouring scFv-Fc
S. cerevisiae yeast biomass containing recombinant pro-
teins was suspended and homogenized in DB450 buffer
(450 mM NaCl, 1 mM CaCl2, 0.001 % Trition X-100,
0.25 M L-Arginine in 10 mM Tris/HCl-buffer pH 7.2)
containing 2 mM PMSF, EDTA-free Complete Protease
Inhibitor Cocktail (Thermo Fisher Scientific) and mechan-
ically disrupted using French press. After centrifugation of
yeast lysate, the supernatant containing recombinant pro-
teins was collected and subjected to the ultracentrifuga-
tion on 30–65 % sucrose gradient and subsequently on
CsCl density gradient ranging to buoyant densities from
1.23 to 1.38 g/mL as described previously [12]. The puri-
fied recombinant proteins were dialyzed against PBS and
analysed by SDS-PAGE.
Electron microscopy
The samples of purified recombinant proteins were placed
on 400-mesh carbon coated palladium grids, negatively
stained with 2 % aqueous uranyl acetate solution and ex-
amined by Morgagni 268 electron microscope (FEI Inc.,
Hillsboro, OR, USA).
Indirect ELISA
Polystyrene microtiter plates (Nerbe plus, Winsen/Luhe,
Germany) were coated with 100 μL per well of the re-
combinant HBsAg ayw (Abcam, Cambridge, UK) diluted
in coating buffer (0.05 M sodium carbonate, pH 9.6) to a
concentration of 5 μg/mL and incubated overnight at
4 °C. The coated plates were blocked with 2 % bovine
serum albumin (BSA) for 1 h at RT and rinsed twice
with PBST. Recombinant pseudotype VLPs were seri-
ally diluted in PBST, added to the wells and incubated
for 1 h at RT. As a negative control, non-modified
HaPyV VP1/VP2 VLPs were used. The plates wererinsed with PBST and incubated for 1 h with the
MAb 3D10 diluted 1:1000 in PBST. The plates were
rinsed with PBST and then incubated for 1 h with
HRP-conjugated rabbit anti-human IgG (Bio-Rad) di-
luted 1:1000 in PBST. The plates were rinsed 5–7
times with PBST. Enzymatic reaction was visualized
by the addition of 100 μL of ready-to-use TMB sub-
strate (Sigma–Aldrich) to each well. After 10 min of incu-
bation at RT, the reaction was stopped by adding 50 μL/
well of 10 % sulphuric acid. The optical density (OD) was
measured at 450 nm (reference filter 620 nm) in a micro-
plate reader (Tecan, Groedig, Austria).HBV-neutralization assay on Tupaia hepatocytes
Neutralization test was performed as described previ-
ously [33]. Briefly, VLPs were preincubated with serum-
derived purified HBV (ID326, genotype D) at a ratio of
10 HBV genomes/hepatocyte for 1 h at 16 °C in Tupaia
hepatocyte medium (THM) and later incubated on pri-
mary Tupaia belangeri hepatocyte cultures (PTHs) for
16 h at 37 °C. As a positive control, the full-length MAb
HB1 previously shown to exhibit the HBV-neutralizing
activity in the in vitro assay was used. As a negative con-
trol, irrelevant pseudotype VLPs harbouring green-
fluorescent protein (VP1/GFP-VP2) were used. The
HBV-neutralization potency of the pseudotype VLPs was
evaluated by measuring the concentration of the newly
produced HBsAg in the culture supernatant on day 11th
after infection. Animals were handled in a full accord-
ance with ethical requirements. Permission to use pri-
mary hepatocytes from Tupaia belangeri was obtained
from the Institutional Review Board of Justus-Liebig
University of Giessen.
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